liver disease

10/29/2013 - 13:26

New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, men are at higher risk of more severe fibrosis compared to women prior to menopause, but liver fibrosis severity is similar in men and post-menopausal women.


06/17/2013 - 09:44

Joseph Pidala, M.D., M.S., assistant member of the Blood and Bone Marrow Transplant and Immunology programs at Moffitt Cancer Center, and colleagues from the Chronic Graft-Versus-Host Disease Consortium have determined that certain gastrointestinal and liver-related types of chronic graft-versus-host disease (GVHD) are associated with worsened quality of life and death.


06/10/2013 - 06:49

New research reveals that transplantation of partial livers from deceased adult and teen donors has become less risky for infants and young children, helping to save these young lives. Findings published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, indicate that risk of organ failure and mortality from partial or split liver transplant was comparable to whole organ transplant in this pediatric population.


05/01/2013 - 11:25

Overconsumption of alcohol creates a different kind of liver damage that affects key organ functions. Long after a hangover, a night of bad decisions might take a bigger toll on the body than previously understood. Described in the current issue of Alcoholism: Clinical & Experimental Research, a study at the University of Missouri has revealed a unique connection between binge drinking and the risk for developing alcoholic liver disease and a variety of other health problems.


08/08/2012 - 17:44

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

03/14/2012 - 11:40

Two novel autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC), discovered by AmberGen, Inc., in collaboration with the Massachusetts General Hospital (MGH), were exclusively licensed to INOVA Diagnostics, Inc., part of the Werfen Group, and a world-leader in clinical assays for autoimmune disease. Discovery of these biomarkers was made possible by the use of AmberGen's proprietary proteomic biomarker discovery pipeline and funded by an Advanced Technology Small Business Innovation Research (SBIR) grant to AmberGen from the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health. Following the work done by AmberGen and MGH, the biomarkers where subjected to further clinical validation by INOVA.